Financials
Business Update | 03-Apr-2023 | 07:00 | RNS |
PDS Update | 30-Mar-2023 | 15:51 | RNS |
PDS Business Update and 2022 Financial Results | 28-Mar-2023 | 15:50 | RNS |
Related party loan to ProAxsis Limited | 28-Feb-2023 | 07:00 | RNS |
PDS completes FDA meeting for triple combination | 27-Feb-2023 | 15:28 | RNS |
Second Price Monitoring Extn | 10-Feb-2023 | 14:05 | RNS |
Price Monitoring Extension | 10-Feb-2023 | 14:00 | RNS |
Second Price Monitoring Extn | 10-Feb-2023 | 11:05 | RNS |
Price Monitoring Extension | 10-Feb-2023 | 11:00 | RNS |
Board Change | 01-Feb-2023 | 07:00 | RNS |
PDS Announces Exclusive Global License Agreement | 03-Jan-2023 | 13:31 | RNS |
PDS Biotech: Median Overall Survival announcement | 28-Dec-2022 | 15:05 | RNS |
Board Changes; Options; Co-Investment Agreement | 12-Dec-2022 | 14:00 | RNS |
Second Price Monitoring Extn | 14-Nov-2022 | 14:05 | RNS |
Price Monitoring Extension | 14-Nov-2022 | 14:00 | RNS |
Currency | UK Pounds |
Share Price | 63.53p |
Change Today | -0.47p |
% Change | -0.74 % |
52 Week High | 72.00 |
52 Week Low | 49.00 |
Volume | 1 |
Shares Issued | 23.95m |
Market Cap | £15.21m |
RiskGrade | 410 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
CEO | Ilian Iliev |
CFO | Stephen Crowe |
You are here: research